PT  - JOURNAL ARTICLE
AU  - Matsuba, Sayo
AU  - Niwa, Satomi
AU  - Muraki, Katsuhiko
AU  - Kanatsuka, Saki
AU  - Nakazono, Yurika
AU  - Hatano, Noriyuki
AU  - Fujii, Masanori
AU  - Zhan, Peng
AU  - Suzuki, Takayoshi
AU  - Ohya, Susumu
TI  - Downregulation of Ca<sup>2+</sup>-Activated Cl<sup>−</sup> Channel TMEM16A by the Inhibition of Histone Deacetylase in TMEM16A-Expressing Cancer Cells
AID  - 10.1124/jpet.114.217315
DP  - 2014 Dec 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 510--518
VI  - 351
IP  - 3
4099  - http://jpet.aspetjournals.org/content/351/3/510.short
4100  - http://jpet.aspetjournals.org/content/351/3/510.full
SO  - J Pharmacol Exp Ther2014 Dec 01; 351
AB  - The Ca2+-activated Cl− channel transmembrane proteins with unknown function 16 A (TMEM16A; also known as anoctamin 1 or discovered on gastrointestinal stromal tumor 1) plays an important role in facilitating the cell growth and metastasis of TMEM16A-expressing cancer cells. Histone deacetylase (HDAC) inhibitors (HDACi) are useful agents for cancer therapy, but it remains unclear whether ion channels are epigenetically regulated by them. Using real-time polymerase chain reaction, Western blot analysis, and whole-cell patch-clamp assays, we found a significant decrease in TMEM16A expression and its functional activity was induced by the vorinostat, a pan-HDACi in TMEM16A-expressing human cancer cell lines, the prostatic cancer cell line PC-3, and the breast cancer cell line YMB-1. TMEM16A downregulation was not induced by the chemotherapy drug paclitaxel in either cell type. Pharmacologic blockade of HDAC3 by 1 μM T247 [N-(2-aminophenyl)-4-[1-(2-thiophen-3-ylethyl)-1H-[1],[2],[3]triazol-4-yl]benzamide], a HDAC3-selective HDACi, elicited a large decrease in TMEM16A expression and functional activity in both cell types, and pharmacologic blockade of HDAC2 by AATB [4-(acetylamino)-N-[2-amino-5-(2-thienyl)phenyl]-benzamide; 300 nM] elicited partial inhibition of TMEM16A expression (∼40%) in both. Pharmacologic blockade of HDAC1 or HDAC6 did not elicit any significant change in TMEM16A expression, respectively. In addition, inhibition of HDAC3 induced by small interfering RNA elicited a large decrease in TMEM16A transcripts in both cell types. Taken together, in malignancies with a frequent gene amplification of TMEM16A, HDAC3 inhibition may exert suppressive effects on cancer cell viability via downregulation of TMEM16A.